Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 18/20 | 0.81 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.81 |
| ▸ | DYRK1B | Q9Y463 | 17/20 | 0.81 |
| ▸ | CLK1 | P49759 | 15/20 | 0.81 |
| ▸ | DYRK3 | O43781 | 15/20 | 0.81 |
| ▸ | CLK4 | Q9HAZ1 | 14/20 | 0.81 |
| ▸ | CLK2 | P49760 | 12/20 | 0.81 |
| ▸ | CLK3 | P49761 | 9/20 | 0.81 |
| ▸ | DYRK4 | Q9NR20 | 8/20 | 0.81 |
| ▸ | GSK3B | P49841 | 6/20 | 0.81 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 6/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 4/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28843039 | 1.00 | DYRK2 (0.81) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL29899850 | 1.00 | DYRK2 (0.81) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL29899824 | 0.91 | DYRK2 (0.84) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL23510515 | 0.91 | DYRK2 (0.84) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL23970521 | 0.90 | DYRK1A (1.00) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL23510496 | 0.90 | DYRK2 (0.81) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL28843061 | 0.90 | DYRK2 (0.81) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL29899965 | 0.90 | DYRK2 (0.81) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL23510450 | 0.89 | DYRK1A (1.00) | DYRK2DYRK1ADYRK1BCLK1DYRK3 | |
| SCHEMBL29015886 | 0.89 | DYRK1A (1.00) | DYRK2DYRK1ADYRK1BCLK1DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929690-B | Novel heterocyclic derivatives having cardiomyocyte proliferative activity for the treatment of heart disease | 同济大学 | 2023-05-05 | — | — | CN | disclosed |
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TONGJI UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TONGJI UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-114929690-A | Novel heterocyclic derivatives with cardiomyocyte proliferative activity for the treatment of cardiac diseases | 同济大学 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TNNI3, TNNT2, MKI67 | DYRK2 3594/4885DYRK1A 3319/4885DYRK1B 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.